Evonik Full-Year Report 2023

A Challenging Year

• Lower demand as a result of the weak economic environment
• Selling prices stable in the specialty chemicals businesses but significant declines at Animal Nutrition and Performance Intermediates
• Sales decreased by 17 percent to €15.3 billion, mainly due to volumes
• Adjusted EBITDA fell 33 percent to €1.7 billion
• High free cash flow of €801 million
• Adjusted net income 65 percent below the prior-year level at €370 million
• Net income was -€465 million as a consequence of high impairment losses
• Outlook for 2024: adjusted EBITDA expected to be between €1.7 billion and €2.0 billion